---
schema_version: "secwatch.filing_event.v1"
accession: "0001736730-25-000041"
form_type: "8-K"
ticker: "CAMP"
cik: "0001736730"
company_name: "Camp4 Therapeutics Corp"
filed_at: "2025-05-16T23:59:59+00:00"
generated_at: "2026-05-21T03:25:13.108479+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CAMP4 reports SYNGAP1 protein increase in NHPs and favorable Phase 1 safety data for UCD program at ASGCT

## Summary
- CMP-SYNGAP-01 restored SYNGAP1 protein to near-normal in haploinsufficient mice and rescued motor/learning defects.
- In NHPs, biweekly intrathecal CMP-SYNGAP-01 achieved ~1.5-fold SYNGAP1 increase in relevant brain regions.
- Phase 1 SAD data for CMP-CPS-001 in 48 healthy volunteers: well tolerated, no serious AEs, dose-dependent PK.
- UCD preclinical: CMP-CPS-001 increased ureagenesis up to 40% in NHPs and reduced ammonia in mice.
- Company plans to expand Phase 1 into OTC heterozygotes with reduced urea cycle function.

## SEC filing metadata
- accession: 0001736730-25-000041
- form_type: 8-K
- ticker: CAMP
- cik: 0001736730
- company_name: Camp4 Therapeutics Corp
- filed_at: 2025-05-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736730/000173673025000041/0001736730-25-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736730/000173673025000041/camp-20250516.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001736730-25-000041
- JSON: https://secwatch.observer/filing/0001736730-25-000041.json
- Plain text: https://secwatch.observer/filing/0001736730-25-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.